[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-metastases":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,42,66,91,121,149,176,201,225,255,275,299,319,340,360,389,409,429,452,481,505,527,549,565,587],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100586706","analysis-of-intramedullary-nail-and-prosthetic-reconstruction-after-surgical-treatment-of-bone-metastases-of-proximal-femur-100586706",false,"NCT06918860","Analysis of Intramedullary Nail and Prosthetic Reconstruction After Surgical Treatment of Bone Metastases of Proximal Femur","Complications, Implant Survival and Functional Results After Surgical Treatment of Bone Metastases of Proximal Femur With Intramedullary Nail or Prosthetic Reconstruction","Inclusion Criteria:\n\n* Male and female adult patients surgically treated between 01\u002F01\u002F2000 and 31\u002F12\u002F2023 in Rizzoli Orthopaedic Institute and in Massachusetts General Hospital.\n* Age ≥18 y (at the time of surgery)\n* Patients with impending or pathological fracture due to bone metastases of the proximal femur (head\u002Fneck, intertrochanteric, subtrochanteric area).\n* Patients who underwent either IMN or THA or HHA or Mega or MegaTHA.\n* Patients with available clinical and imaging data.\n\nExclusion Criteria:\n\n* Patients with pathological or impending fracture of proximal femur due to primary bone tumor.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The investigators will collect data of patients treated surgically for impending or pathological fracture of the proximal femur due to bone metastases between 01\u002F01\u002F2000 and 31\u002F12\u002F2023 with IMN or THA or HHA or MegaTHA or Mega.\n\nAfter pre-screening the databases of the respective sites, the investigators expect to find approximately a total of 600 patients. A review will be made from the medical records, radiological imaging, and histological data of partecipants.",[25],"Bone Metastases",[27,28],"bone metastases","proximal femur","RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2024-05-30",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"Costantino Errani","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100530615","arterial-embolization-for-the-treatment-of-bone-metastases-prospective-observational-study-100530615","NCT06189079","Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study","Embolizzazione Arteriosa Per il Trattamento Delle Metastasi Ossee: Studio Osservazionale Prospettico","EMBONEMET","Inclusion Criteria:\n\n* Patients of either sex of age or older who are candidates for embolization therapy\n* Life expectancy \\> 3 months\n* Single metastatic or oligometastatic.\n* Plurimetastatic if a particular site is causing painful symptoms or at risk for pathologic rupture\n\nExclusion Criteria:\n\n* Patients with life expectancy \\\u003C3 months or severe functional status impairment (ASA 4)\n* Patients with hypovascular metastasis documented by angiography or MRI perfusion study with MDC.\n* Patients with coagulation deficiency or plateletopenic patients.\n* Patients with documented active infection.",{"count":51,"type":21},60,"1 Year","To date, arterial embolization constitutes one of the most popular methods in minimally invasive treatment of bone metastases, allowing good results in terms of pain reduction, local control of disease and reduction of peri-operative bleeding, with low invasiveness.",[25],[56],"Arterial embolization","2026-05-11",{"date":59,"type":33},"2026-05-12",{"date":61,"type":33},"2023-05-10",{"date":63,"type":21},"2028-08",{"name":65,"class":40},"Istituto Ortopedico Rizzoli",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100623036","registry-for-bone-metastases-100623036","NCT07391410","Registry for Bone Metastases","The International Bone Metastasis Registry","Inclusion Criteria:\n\n* Age ≥22 years\n* Biopsy-proven or clinically obvious metastatic bone disease\n* Symptomatic bone lesion requiring intervention\n* This includes but is not limited to radiotherapy, cryotherapy, radiofrequency ablation, operative fixation, prosthetic replacement, amputation, or any combination of the above\n\nExclusion Criteria:\n\n* Age \\\u003C22 years","22 Years",{"count":75,"type":21},500,"10 Years","The purpose of this study is to learn more about symptomatic bone metastases. This study is an international patient registry of people with symptomatic bone metastases. A patient registry is a database - a collection of health information - about a group of people, and it is usually focused on a specific diagnosis or condition.",[25],[80],"23-175","2026-04-21",{"date":83,"type":33},"2026-04-22",{"date":85,"type":33},"2026-01-13",{"date":87,"type":21},"2031-01",{"name":89,"class":40},"Memorial Sloan Kettering Cancer Center",7,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100348956","phase-3-post-op-pain-control-for-prophylactic-intramedullary-nailing-100348956","NCT03823534","Post-Op Pain Control for Prophylactic Intramedullary Nailing.","Inclusion Criteria:\n\n1. Femoral Shaft or Neck bone lesion\n2. 18 years old or greater\n3. Plan to undergo prophylactic intramedullary nailing of one femur\n\nExclusion Criteria:\n\n1. Concurrent pathologic fracture\n2. History of advanced renal impairment (eGFR\\\u003C30mL\u002Fmin)\n3. History of Peptic Ulcer Disease with bleeding or requiring hospitalization\n4. History of NSAID or aspirin allergy\n5. Concurrent chemotherapy regimen that prevents NSAID use\n6. History of liver disease that precludes use of toradol\n7. History of heart failure or cardiovascular disease that precludes toradol usage\n8. Pregnancy\n9. History of narcotic allergy resulting in anaphylaxis\n10. Patients with coagulation disorders or those who require concomitant use of anticoagulant or anti- platelet therapy during the treatment phase of the study.\n11. Patients with acetaminophen allergies resulting in anaphylaxis\n12. Current use of the medication probenecid\n13. Current use of the medication Pentoxifylline\n14. History of aspirin induced asthma.\n15. Known history of opioid dependence, abuse, or addiction.\n16. Bilateral IMN of the femurs",{"count":51,"type":21},"INTERVENTIONAL",[100],"PHASE3","Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to NSAID use. Orthopedic oncology, however, has a unique subset of patients that undergo prophylactic placement of intramedullary femoral nails. Because no fracture is present, these patients do not rely on inflammatory healing factors, allowing for post-op NSAID use. This study sets out to determine the effect of post-op toradol use in addition to opioids compared to solely opioids in patients undergoing prophylactic nailing of the femur.",[25,103,104,105,106],"Lymphoma","Multiple Myeloma","Opioid Use","Pain",[108,109,110,27,111,112],"Toradol","Ketorolac","Prophylactic intramedullary nail","Opioid use","post-operative pain","2026-04-17",{"date":83,"type":33},{"date":116,"type":33},"2019-02-20",{"date":118,"type":21},"2027-03-31",{"name":120,"class":40},"St. Louis University",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":98,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100634512","phase-2-prophylactic-radiotherapy-to-prevent-bone-complications-in-patients-with-metastatic-solid-cancers-100634512","NCT07540650","Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers","A Randomized Controlled Trial of Early Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers","pRevenT","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed solid malignancy\n* Metastatic disease confirmed by imaging (CT, MRI, or PET-CT)\n* Presence of up to five high-risk bone metastases\n* High-risk bone metastases defined according to protocol criteria\n* Asymptomatic or minimally symptomatic bone metastases (not requiring opioid analgesics)\n* ECOG performance status 0-2\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Prior radiotherapy to the index bone metastases preventing safe treatment planning\n* Symptomatic bone metastases requiring immediate palliative radiotherapy\n* Evidence of spinal cord compression\n* Bone metastases causing significant pain requiring opioid analgesics\n* Oligometastatic disease suitable for radical treatment\n* Leptomeningeal disease\n* ECOG performance status ≥3\n* Life expectancy less than 3 months\n* Any condition that, in the investigator's opinion, would interfere with study participation or assessment",{"count":130,"type":21},90,[132],"PHASE2","This is a prospective, randomized, single-center clinical trial evaluating whether early prophylactic radiotherapy to high-risk asymptomatic or minimally symptomatic bone metastases reduces the 1-year rate of skeletal-related events (SREs) in patients with metastatic solid cancers. Patients will be randomized in a 1:1 ratio to receive either standard of care systemic therapy or observation, or prophylactic radiotherapy in addition to standard of care. The primary endpoint is the 1-year rate of SREs. Secondary endpoints include adverse events, quality of life, economic burden, pain-free survival, and overall survival.",[25,135],"Metastatic Solid Tumor",[137,138],"prophylactic radiotherapy","early radiotherapy","NOT_YET_RECRUITING","2026-04-14",{"date":142,"type":33},"2026-04-20",{"date":144,"type":21},"2026-04",{"date":146,"type":21},"2029-02",{"name":148,"class":40},"Institute of Oncology Ljubljana",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":98,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":41},"100634306","phase-2-denosumab-strategy-for-liver-cancer-with-bone-metastases-100634306","NCT07537972","Denosumab Strategy for Liver Cancer With Bone Metastases","Early Denosumab Plus a Uniform PD-1-Based Systemic Therapy Versus Delayed\u002FRescue Bone-Modifying Strategy in Hepatocellular Carcinoma With Bone Metastases: A Single-Center Prospective Randomized Controlled Exploratory Study","Inclusion Criteria:\n\n* Age 18 to 75 years\n* Hepatocellular carcinoma confirmed by imaging and\u002For histology according to current institutional diagnostic standards\n* Bone metastasis confirmed by CT, MRI, bone scintigraphy, PET-CT, or pathology\n* ECOG performance status 0 to 1\n* Child-Pugh class A or stable Child-Pugh B7 judged suitable for systemic treatment\n* At least 1 measurable intrahepatic lesion at baseline and planned initiation of a PD-1 inhibitor-based systemic therapy\n* Estimated life expectancy of at least 3 months\n* Adequate organ function according to protocol-defined laboratory criteria\n* Corrected serum calcium within the normal range, or corrected to protocol-defined range after calcium\u002Fvitamin D supplementation\n* Completed baseline oral\u002Fdental risk assessment and willingness to avoid nonessential invasive dental procedures during the study\n* Written informed consent and willingness to comply with study visits, questionnaires, sample collection, and follow-up\n\nExclusion Criteria:\n\n* Prior treatment with PD-1, PD-L1, CTLA-4, or other immune checkpoint inhibitors\n* Receipt of denosumab or intravenous\u002Foral bisphosphonates for tumor-related bone disease within 6 months before randomization\n* Uncorrected hypocalcemia or severe vitamin D deficiency that cannot be corrected promptly\n* Current or prior osteonecrosis of the jaw, jaw osteomyelitis, or high-risk dental condition requiring near-term extraction, implantation, or other invasive dental procedures that cannot be deferred\n* Active autoimmune disease or need for systemic immunosuppressive treatment, except for low-risk conditions judged acceptable by the investigator\n* Life-threatening bone complication within 4 weeks before randomization that is not stabilized, including unresolved spinal cord compression or clinically significant spinal instability\n* Active infection, including uncontrolled bacterial or fungal infection, active tuberculosis, or other condition judged unsafe for systemic treatment\n* Symptomatic or uncontrolled central nervous system metastases\n* Pregnancy or breastfeeding, or refusal to use effective contraception when applicable\n* Known severe hypersensitivity to denosumab or any study-related treatment component\n* Another active malignancy, poor compliance, or any condition judged by the investigator to make study participation unsuitable","75 Years",{"count":158,"type":21},50,[132],"This study will evaluate whether starting denosumab early, together with a locked uniform PD-1-based systemic therapy, can reduce skeletal-related events and delay worsening bone pain compared with a delayed\u002Frescue bone-modifying strategy in patients with hepatocellular carcinoma and bone metastases. Participants will be randomly assigned in a 1:1 ratio to receive either early denosumab plus the same PD-1-based systemic therapy or the same systemic therapy with no routine prophylactic bone-modifying agent at baseline and rescue treatment only when predefined triggers occur. The primary outcome is skeletal-related event-free survival. Secondary outcomes include time to first skeletal-related event, pain outcomes, quality of life, intrahepatic antitumor activity at Week 12, progression-free survival, overall survival, and safety.",[162,25],"Hepatocellular Carcinoma (HCC)",[164,25,165,166,167],"Denosumab","Skeletal-Related Events","Bone Pain","PD-1 Inhibitor","2026-04-12",{"date":113,"type":33},{"date":171,"type":21},"2026-05-01",{"date":173,"type":21},"2029-06-30",{"name":175,"class":40},"Tongji Hospital",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":185,"studyType":22,"phases":4,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":41},"100236481","prospective-evaluation-of-interventional-studies-on-bone-metastases---the-present-cohort-100236481","NCT02356497","Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort","PRESENT","Inclusion Criteria:\n\n* Histologic proof of malignancy;\n* Radiographic or histologic proof of metastatic bone disease;\n* Undergoing radiotherapy;\n* Age \\> 18 years;\n* Informed consent - at least - for use of routinely collected clinical data.\n\nExclusion Criteria:\n\n* Mentally incompetent patients;\n* Life expectancy \\\u003C 1 week indicated by the treating physician.",{"count":184,"type":21},2500,"3 Years","Bone metastases are frequent distant manifestations of cancer, with pain as a common and devastating consequence. The primary treatment for painful bone metastases, external beam radiation therapy, is moderately effective: about 60% of patients who undergo conventional radiotherapy experience (partial) pain relief. Several factors associated with treatment failure have been identified, but no attempts have been made to collapse these factors into a clinically useful prediction tool to predict treatment response. In addition, to aid in therapy selection based on expected survival time, development of survival models is essential. Finally, we need innovative treatments as alternatives or additive to standard treatment options to improve quality of life (QoL). For these reasons, we set up the PRESENT cohort study, recruiting patients at the departments of radiation oncology and orthopedic surgery.\n\nWe aim to provide detailed information about clinical data, create an infrastructure for efficient, fast and pragmatic evaluation and implementation of innovative interventions, as well as development of accurate new prediction tools.",[25],[189,190,191],"Bone metastases","Metastatic bone disease","Multi-trial facility","2026-03-18",{"date":194,"type":33},"2026-03-19",{"date":196,"type":33},"2013-06",{"date":198,"type":21},"2035-12",{"name":200,"class":40},"UMC Utrecht",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":98,"phases":210,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100625960","sbrt-technique-implementation-for-spinal-metastases-irradiation-100625960","NCT07429422","SBRT Technique Implementation for Spinal Metastases Irradiation","Program SBRT Technique Implementation in Spinal Metastases Irradiation","Inclusion Criteria:\n\n* Adult patients (≥18 years) with spinal metastases or spinal tumors referred for stereotactic body radiotherapy (SBRT).\n* Patients eligible for SBRT treatment according to the institutional SBRT spine protocol.\n* Ability to undergo CT simulation, immobilization, and image-guided radiotherapy procedures.\n\nExclusion Criteria:\n\n* Inability to tolerate SBRT positioning or immobilization.\n* Clinical situations requiring urgent surgical intervention or alternative treatment.\n* Other medical conditions that prevent safe SBRT delivery.",{"count":209,"type":21},100,[211],"NA","Stereotactic body radiotherapy (SBRT) is a highly precise, image-guided radiotherapy technique delivering 1-5 high-dose fractions to spinal metastases. Compared with conventional radiotherapy, SBRT enables delivery of a higher biologically effective dose while maintaining high precision.\n\nThe Institute of Oncology Ljubljana initiated spinal SBRT treatments in 2017 and introduced an institutional SBRT spine protocol in 2019. As SBRT is technically demanding, strict adherence to standardized planning and delivery procedures is essential to ensure treatment quality and patient safety.\n\nThis clinical program aims to support structured implementation and continuous development of the institutional SBRT spine protocol in routine clinical practice. The study prospectively evaluates treatment-related toxicity and local tumor control following SBRT for spinal metastases in order to monitor treatment safety and effectiveness within the institutional program.",[214,215,25],"Spinal Metastases","Spinal Tumors","2026-02-20",{"date":218,"type":33},"2026-02-24",{"date":220,"type":33},"2021-11-01",{"date":222,"type":21},"2026-12-31",{"name":148,"class":40},2,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":98,"phases":235,"briefSummary":236,"conditions":237,"keywords":241,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":254},"100604173","early-radiotherapy-versus-observation-for-high-risk-asymptomatic-or-minimally-symptomatic-bone-metastases-100604173","NCT07146074","Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases","Phase III Randomized Trial for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases: Early Radiotherapy Versus Observation","HERMES","Inclusion Criteria:\n\n* I1: Histologically confirmed solid tumor malignancy (with polymetastastic spread (≥ 3 metastases))\n* I2: High-risk bone metastasis(es) that is (are) asymptomatic or minimally symptomatic:\n\n  \\*Asymptomatic or minimally symptomatic is defined as follows: O Numeric Pain Rating Scale (NRS) score ≤2 for the specific lesion(s)\n\n  \\*High-risk is defined as follows (i.e. at least one of the following points must be applicable): O Bulky site of disease in bone (diameter ≥ 2 cm) O Disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints O Disease in long bones with cortical involvement of \\>1\u002F3 in proportion to the diameter of the bone (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpals, phalanges) O Disease in vertebrae of the junctional spine (C1-2, C7- T1, T12-L1, L5-S1) and\u002For disease with posterior element involvement or epidural extension (Bilsky epidural compression score 1a-3) \\[Bilsky et al\\]. The posterior elements of the spine consist of the pedicles, laminae, facets (articular processes), transverse processes, and the spinous process.\n* I3: Number of Risk Factors (NRF) prognostic score 0-2\n* I4: Age ≥ 18 years\n* I5: Ability to provide informed consent (either by the patient or by a legally authorized representative)\n* I6: A female participant is eligible to participate if she confirms not to be pregnant at screening, and one of the following conditions applies:\n\nIs not a woman of child bearing potential or A woman of child bearing potential must confirm that she is not pregnant at screening and must agree to use a very effective method of birth control\n\nExclusion Criteria:\n\n* E1: Previous RT to the target treatment site(s)\n* E2: NRF prognostic score 3\n* E3: Serious medical co-morbidities that preclude radiotherapy\n* E4: Bone lesion complicated with a pathological fracture or impending pathologic fracture for which prophylactic stabilization is recommended, characterized by Mirels score of ≥9 \\[Mirels et al\\].\n* E5: Spinal metastasis with SINS score \\>13 requiring upfront neurosurgical stabilization \\[Fourney et al\\].\n* E6: More than 5 high-risk asymptomatic or minimally symptomatic metastatic bone locations\n* E7: Patient already included in another clinical trial that would interfere with the HERMES clinical trial, as assessed by the Investigator.",{"count":234,"type":21},120,[211],"The goal of this clinical trial is to learn whether radiotherapy (i.e. treatment with ionizing radiation to destroy cancer cells) can prevent symptoms in patients with metastatic cancer, having high-risk bone metastases that currently result in no or only mild symptoms. High-risk bone metastases are bone metastases at high-risk of developing bone complications, such as fractures or myelum compression.\n\nThe main questions this study aims to answer are:\n\n* Can preventive radiation of high-risk asymptomatic or minimally symptomatic bone metastases (and observation or medication) decrease the number of skeletal related events (i.e. bone complications due to bone metastases) in patients with metastatic cancer?\n* Can preventive radiation of high-risk asymptomatic or minimally symptomatic bone metastases (and observation or medication) decrease the need for hospitalization related to such bone metastases, improve overall survival and (health-related) quality of life?\n* What are the side effects of preventive radiation of high-risk asymptomatic or minimally symptomatic bone metastases?\n\nResearchers will compare 2 treatment groups in order to answer the questions listed above: 1 group treated with medication or observation alone (group A) and 1 group treated with medication or observation and preventive radiotherapy (group B).\n\nParticipants will\n\n* be screened to assess whether they are eligible to participate in the study.\n* be randomized (i.e. drawn) into the 2 treatment groups mentioned above.\n* be treated with preventive radiotherapy if they were drawn in treatment group B.\n* need to attend follow-up visits (may be via teleconsultation) at 1, 3, 6, 12, 18 and 24 months after date of randomization during which safety and efficacy is monitored. During these follow-up visits, the general health condition of the participant is evaluated, the occurrence of any bone complication, the medications taken by the participant are registered, the degree of pain and location of the high-risk bone metastases are determined and possible side effects are registered. Furthermore, the participant needs to complete 2 questionnaires at each visit regarding his\u002Fher quality of life.",[238,25,239,240],"Solid Neoplasms","Asymptomatic or Minimally Symptomatic","High Risk for Skeletal Events",[189,242,243,244,245],"Randomized","Radiotherapy","Symptomatic skeletal events","Preventive","2026-01-16",{"date":248,"type":33},"2026-01-20",{"date":250,"type":33},"2025-02-05",{"date":146,"type":21},{"name":253,"class":40},"Cancer Research Antwerp",8,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":261,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":98,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":41},"100521119","phase-3-a-phase-iii-randomized-trial-comparing-stereotactic-body-radiation-therapy-sbrt-vs-conventional-palliative-radiation-therapy-for-painful-bone-metastases-100521119","NCT06065449","A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases","Inclusion Criteria:\n\n* Patients with pathologic diagnosis of solid primary malignancy with any radiographic report of bone metastases including but not limited to plain x-ray, bone scan, CT scan, MRI, PET\u002FCT scan, PSMA scan, PET fluciclovine scan. The exception is patients diagnosed with multiple myeloma are eligible.\n* Patients with any pain or discomfort at proposed treatment site.\n* Patients with life expectancy of 3 months or greater.\n* Patients able to complete pain assessment and quality of life surveys.\n* Patients with multiple osseous sites are eligible; however, should not treat more than three separate isocenters concurrently. Additional isocenters can be treated sequentially.\n* Patients with prior surgery for osseous metastases are eligible.\n* Patients age 18 years or older. Pediatric patients are usually enrolled on pediatric protocols. There are no adverse data available for patients \\\u003C 18 years of age treated with SBRT, therefore children are excluded from this study.\n* Patients may receive systemic therapy including chemotherapy, targeted therapy, immunotherapy, or other systemic agents up to and during radiation at treating physician's discretion per standard of care.\n* Patients must have adequate organ and marrow function as defined below:\n\nplatelets ≥ 40,000\u002FmcL\n\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* The effects of radiation therapy on the developing human fetus are unknown. For this reason and because radiation therapy as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n  1. Postmenopausal (no menses in greater than or equal to 12 consecutive months)\n  2. History of hysterectomy or bilateral salpingo-oophorectomy.\n  3. Ovarian Failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy)\n  4. History of bilateral tubal ligation or another surgical sterilization procedure.\n* Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 2 weeks after completion of radiation therapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients with prior radiation therapy to the proposed treatment site.\n* Patient with current, un-treated cord compression at treatment site.\n* Patients with a radiographic or pathologic fracture at the proposed treatment site that is not mechanically stable. If this is stabilized mechanically or seen by orthopedic surgery, this site is eligible for enrollment and treated on protocol\n* Patients with metastases to hand and feet.\n* Patients with previously treated with radioactive isotope (e.g. Sr 89) within 30 days of randomization. This can have concomitant effects with radiation therapy.\n* Patients with spinal metastases along cervical, thoracic, or lumbar spine are not eligible. However, if the primary site invades the paraspinal or spine region, these are eligible.\n* Pregnant patients are not eligible.",true,{"count":263,"type":21},220,[100],"To compare increasing doses and different treatment schedules of stereotactic body radiation therapy (SBRT) against standard treatment scheduling.",[25],{"date":268,"type":33},"2026-01-14",{"date":270,"type":33},"2024-01-24",{"date":272,"type":21},"2027-06-27",{"name":274,"class":40},"M.D. Anderson Cancer Center",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":52,"studyType":22,"phases":4,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":298},"100553043","bone-metastases-registry-for-patients-undergoing-cryoablation-with-curative-purpose-100553043","NCT06480955","BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe","BOREALIS","Inclusion Criteria:\n\n* Bone metastases in patients with oligometastatic disease (\\\u003C5 bone\u002Fvisceral metastases) or bone oligo-progressive disease (visceral or osseous multi-metastatic disease stable under systemic treatment except 1-3 progressing bone metastases) from solid tumours;\n* Number of target lesions ≤ 3\n* Size of target lesion(s) \\\u003C 5 cm (largest diameter);\n* Referral to local ablative treatment by multidisciplinary tumour board (MDTB);\n* Treatment by percutaneous cryoablation with curative intent (i.e., complete tumour destruction) assessed as technically feasible by the IR in charge;\n* Procedure performed with a cryoablation system from Boston Scientific.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old;\n* Incapacity or refusal to give informed consent;\n* Ongoing pregnancy;\n* Health status not compatible with the minimum meaningful follow-up period (i.e., 12 months):\n\n  * Karnofsky Performance Scale \\\u003C 60%, or\n  * Bone metastases originating from rapidly evolving tumour histologies not allowing reasonable life expectancy of at least 12 months, or\n  * Life expectancy \\\u003C 12 months\n* Infection of treatment site or systemic infection;\n* Uncorrectable coagulopathy;\n* Haematological disease (including multiple myeloma and plasmacytoma);\n* Concomitant radiation therapy or radiation therapy within 12 weeks before the planned cryoablation procedure.",{"count":158,"type":21},"BOREALIS is a multicentre, prospective, observational cohort study designed to investigate the effectiveness, feasibility, safety and impact on pain and quality of life of curative-intent cryoablation for the treatment of bone metastases in patients with oligometastatic or bone oligo-progressive disease.",[25],[286,189,287,288],"Cryoablation Oligo-progressive disease","Oligometastatic Disease","Oligo-progressive disease","2025-12-23",{"date":291,"type":33},"2025-12-30",{"date":293,"type":33},"2025-04-01",{"date":295,"type":21},"2028-04",{"name":297,"class":40},"Cardiovascular and Interventional Radiological Society of Europe",5,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":318,"locationsCount":41},"100556418","fracture-risk-evaluation-of-bone-metastases-derived-from-carcinoma-100556418","NCT06524843","Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma","Generation of Synthetic Patient Data (RAW) for Risk Evaluation of Bone Metastases Derived From Carcinoma","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases\n* Availability of imaging and clinical data\n* Availability of at least one follow-up during the last 12 months form diagnosis\n\nExclusion Criteria:\n\n* At least one inclusion creteria not met",{"count":307,"type":21},250,"From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01\u002F01\u002F2010 to 31\u002F12\u002F2022.\n\nA review will be made from the medical records, radiological imaging, and histological data of these patients",[25],[189,311],"Prediction model","2025-12-12",{"date":314,"type":33},"2025-12-15",{"date":316,"type":33},"2024-09-23",{"date":37,"type":21},{"name":39,"class":40},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":98,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":336,"leadSponsor":338,"locationsCount":41},"100608493","simulation-free-single-fraction-palliative-radiation-therapy-for-treatment-of-bone-metastases-100608493","NCT07202273","Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases","A Feasibility Study of Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases (SIM-FREE RT)","SIM-FREE RT","Inclusion Criteria:\n\n* Participant aged ≥ 18 years.\n* Diagnosis of any cancer with one to two painful and treatable metastatic bone lesions.\n* Bone metastases are causing pain or instability in the opinion of the treating investigator.\n* Amenable to single fraction radiation therapy per the discretion of the treating physician.\n* CT collected within 60 days of registration with adequate visualization of target site as determined by the treating investigator.\n* ECOG Performance Status ≤ 2.\n* Participants must adhere to the following sex and contraceptive\u002Fbarrier requirements:\n\n  * If participant is of childbearing potential, they must have a negative pregnancy test ≤ 14 days before the planned date of radiation therapy. This may be completed on the day of radiation if results from the pregnancy test are available for review before treatment.\n  * For participants of non-child bearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n    * \\\u003C 50 years of age:\n\n      * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n      * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n\n        ---≥ 50 years of age:\n      * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n      * Had radiation-induced menopause with last menses \\>1 year ago; or\n      * Had chemotherapy-induced menopause with last menses \\>1 year ago\n    * Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Evidence of spinal cord compression caused by the bone metastases to be treated.\n* Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.\n* Participants taking prohibited medications as described in Section 6.7.1.",{"count":328,"type":21},40,[211],"The goal of this study is to provide proof that patients can be treated with simulation-free, single-fraction palliative radiation therapy with a single in-person visit.",[25],"2025-11-03",{"date":334,"type":33},"2025-11-05",{"date":332,"type":33},{"date":337,"type":21},"2028-10",{"name":339,"class":40},"University of Utah",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100608087","validation-of-whole-body-petct-foundation-model-100608087","NCT07196995","Validation of Whole Body PET\u002FCT Foundation Model","Prospective Multicenter Validation of Whole Body PET\u002FCT Foundation Model for Bone Lesion Detection","Inclusion Criteria:\n\n* With suspicious lesion in the bone or with elevated serum tumor markers or patient insist\n* Over 18 years\n\nExclusion Criteria:\n\n* Active infection at or adjacent to the puncture site\n* Severe coagulation disorders that cannot be corrected\n* Random blood glucose \\> 11.1 mmol\u002FL\n* Refuse for pathological confirmation or follow-up\n* Extremely debilitated patients or those unable to cooperate",{"count":348,"type":21},180,"Prospective multicenter study to validate the diagnostic performance of whole body PET\u002FCT foundation model for bone lesion detection",[25],"2025-09-29",{"date":353,"type":33},"2025-10-03",{"date":355,"type":21},"2025-10-16",{"date":357,"type":21},"2026-12-15",{"name":359,"class":40},"Shanghai 6th People's Hospital",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":369,"conditions":370,"keywords":374,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":384,"leadSponsor":386,"locationsCount":388},"100607238","dual-energy-ct---a-tool-for-delineation-of-tumor-and-organs-at-risk-in-radiotherapy-100607238","NCT07185958","Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy","DART","Inclusion Criteria:\n\n* ECOG performance status (PS) 0-2\n* Assessed to be able to complete the protocol scanning regime\n* Referred for RT\n* For head and neck cancer patients, a PET\u002FCT scan must have been performed during the diagnostic evaluation for cancer\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Previous RT in the same anatomical area now referred for RT\n* Previous surgery in the same anatomical area now referred for RT\n* Participation in conflicting protocols\n* If relevant for the protocol scanning regime: Allergic to contrast agent\n* If relevant for the protocol scanning regime: Contraindication to iodine-based contrast agent for CT (as determined by the physician)\n* If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician)\n* If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.)\n* Incapable of understanding the patient information",{"count":368,"type":21},80,"The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and\u002For contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H\\&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H\\&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)\u002FCT scan currently used in clinical practice.",[371,25,372,373],"Brain Metastases","Head and Neck Cancer","Lung Cancer",[375,376,377,378,379],"tumor delineation","organs at risk delineation","dual-energy CT","DECT","radiotherapy","2025-09-15",{"date":382,"type":33},"2025-09-22",{"date":382,"type":21},{"date":385,"type":21},"2028-03-21",{"name":387,"class":40},"Aalborg University Hospital",3,{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":41},"100541852","radiotherapy-treatments-for-neoplasms-of-the-limbs-100541852","NCT06335251","Radiotherapy Treatments for Neoplasms of the Limbs","Inclusion Criteria:\n\n1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the upper and lower limbs for:\n\n   Primary bone tumors, Primary soft tissue tumors, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system and skin, Secondary metastases from various origins localized in that district.\n2. Signed informed consent\n\nExclusion Criteria:\n\n1\\. Radiotherapy in districts other than limbs.",{"count":396,"type":21},3000,"In this observational study patients treated at European Institute of Oncology with radiotherapy to limbs will be included",[399,25],"Bone Neoplasms","2025-08-22",{"date":402,"type":33},"2025-08-28",{"date":404,"type":33},"2018-02-22",{"date":406,"type":21},"2025-12-31",{"name":408,"class":40},"European Institute of Oncology",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":415,"maxAge":156,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":41},"100305847","abductor-reattachment-methods-in-proximal-femur-replacements-what-is-the-best-method-100305847","NCT03261544","Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?","Inclusion Criteria:\n\n• Has undergone or is scheduled for proximal femur replacement by an Ortho Oncology surgeon\n\nExclusion Criteria:\n\n* Non-ambulatory before or after the procedure\n* Subjects who, in the opinion of the investigator, have not or likely will not complete at least some portion of the investigator's recommended follow-up","16 Years",{"count":158,"type":21},"The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique. The investigators hypothesize that those patients who receive reattachment of the abductors directly into the prosthesis will have better functional outcomes overall. Furthermore, the investigators plan to develop a simple, cost effective, and reproducible method to assess abductor function at clinical post-operative visits through plain radiographs.",[419,25,420],"Sarcoma","Proximal Femur Replacement","2025-08-16",{"date":400,"type":33},{"date":424,"type":33},"2017-11-10",{"date":426,"type":21},"2028-11",{"name":428,"class":40},"Duke University",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":98,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":224},"100470454","stereotactic-multiple-fraction-radiotherapy-for-non-spine-bone-metastases-100470454","NCT05406063","Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases","Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases a Multicentre Prospective, Open Label, Randomised Controlled Phase 3 Non-inferiority Clinical Trial","SMILE","Inclusion Criteria:\n\n* Personally signed and dated written informed consent,\n* Histological diagnosis of malignancy,\n* Histologically or radiologically diagnosed bone metastasis,\n* Age ≥ 18 years\n* Pain or under pain control medication\n\nExclusion Criteria:\n\n* Pregnant or lactating women,\n* Women of childbearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment,\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.,\n* Prior radiotherapy to the intended treatment site,\n* Lesions \\> 5cm in maximum diameter,\n* Prior treatment with radioactive isotopes within 30 days of randomisation,\n* Spinal column, hands, feet, or head as intended treatment site,- Fracture at the intended treatment site,\n* Surgery required or previous surgery at the intended treatment site\n* Instability of the intended treatment site.",{"count":438,"type":21},162,[211],"To investigate, whether multi-fraction stereotactic body radiation therapy (SBRT) within 3 treatment fractions is non-inferior to the current standard of care of 5 fraction SBRT regarding pain response at 3 months after radiotherapy.",[442,25,106],"Radiation Therapy","2025-05-19",{"date":445,"type":33},"2025-05-22",{"date":447,"type":33},"2022-06-01",{"date":449,"type":21},"2026-05-31",{"name":451,"class":40},"Kantonsspital Winterthur KSW",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":41},"100502684","metastatic-pathologic-fractures-short-term-results-100502684","NCT05825456","Metastatic Pathologic Fractures, Short Term Results","Metastatic Pathologic Fractures: Short Term Results of Endoprosthetic Reconstruction, Intramedullary Nail and Open Reduction Internal Fixation","Inclusion Criteria:\n\n* metastatic pathologic fracture\n* operated via endoprosthesis, intramedullary nail or plate \\& screws\n\nExclusion Criteria:\n\n* primary bone tumor\n* conservative management\n* neuromuscular disease\n* periprosthetic fractures\n* less than 1 month follow up",{"count":460,"type":21},200,"This is a single center prospective study to compare the short term results of prosthesis, nail and plate-screw surgeries for metastatic pathologic fractures.",[463,25,464],"Pathologic Fracture","Metastatic Cancer",[466,467,468,469,470,471],"bone metastasis","pathologic fracture","endoprosthetic reconstruction","intramedullary nailing","open reduction internal fixation","plate and screws","2025-03-01",{"date":474,"type":33},"2025-03-05",{"date":476,"type":33},"2022-01-01",{"date":478,"type":21},"2026-01-01",{"name":480,"class":40},"Ankara University",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":488,"minAge":18,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":98,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":41},"100557498","phase-2-tislelizumab-combined-with-nab-paclitaxel-for-first-line-treatment-of-advanced-triple-negative-breast-cancer-with-bone-metastasisan-exploratory-single-arm-multicenter-phase-ii-clinical-study-100557498","NCT06538896","Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study","Exploratory Single-Arm, Multicenter Phase II Study of Tislelizumab Combined with Nab-Paclitaxel As First Line Treatment for Patients of Triple-negative Breast Cancer(TNBC) with Bone Metastasis","Inclusion Criteria:\n\n1. Female, aged ≥18 years and \\\u003C70 years;\n2. Metastatic triple-negative breast cancer (TNBC) confirmed by histological examination, i.e., negative for human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR);\n3. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;\n4. Expected survival time ≥3 months;\n5. ≥1 bone metastasis confirmed by histology or imaging. There must be at least one measurable lesion defined according to RECIST 1.1 criteria. For lesions that have undergone previous radiotherapy, they can only be considered measurable if there is definite disease progression after radiotherapy;\n6. Patients with initially diagnosed stage IV (staging based on AJCC 8th edition) or recurrent\u002Fmetastatic TNBC who are not suitable for surgical treatment, and have not received prior systemic therapy for advanced disease. Prior neoadjuvant and\u002For adjuvant therapy with taxanes and other antitumor treatments is allowed, but it must meet the criteria of no progression after neoadjuvant therapy, and the time interval between the end of taxane (neo)adjuvant therapy and recurrence\u002Fmetastasis must be ≥12 months, and the time interval between the end of capecitabine (neo)adjuvant therapy and recurrence\u002Fmetastasis must be ≥6 months. If immunotherapy was conducted during neoadjuvant phase, the time interval between the last immunotherapy and the screening enrollment for this study must be ≥24 months;\n7. Prior local radiotherapy for metastatic sites is allowed, with no limit on the time of completion of radiotherapy, but the patient must have recovered from the effects of radiotherapy before enrolled;\n8. Function of vital organs meets the protocol requirements within 1 week before the first administration of the study drug;\n9. Patients voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Currently participating in other clinical studies;\n2. Untreated central nervous system disease (patients with asymptomatic central nervous system metastases are allowed);\n3. Carcinomatous meningitis;\n4. Uncontrolled pleural effusion, ascites, or pericardial effusion (patients with indwelling drainage tubes are allowed to enroll);\n5. Existing neuropathy ≥ Grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0);\n6. Uncontrolled tumor-related pain; patients requiring analgesia are allowed to enroll if they have a stable and effective analgesia regimen at the time of enrollment;\n7. Patients expected to use any other systemic or local anti-tumor therapy during the study treatment; local radiotherapy for symptomatic isolated lesions or isolated brain metastases is allowed after evaluation and approval by the investigator; local radiotherapy is not allowed for all target lesions during the study treatment;\n8. Diagnosis of other malignancies within 5 years. Exceptions include: radically treated early-stage malignancies (carcinoma in situ or stage I tumors), such as adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer;\n9. Currently pregnant\u002Flactating women;\n10. Evidence of significant comorbidities that may affect the patients' compliance with the study protocol or interpretation of the study results;\n11. Severe cardiovascular disease;\n12. Known allergy to any drug used in the study;\n13. Patients with any active autoimmune disease requiring systemic treatment (i.e., use of disease-modulating drugs, corticosteroids, or immunosuppressive drugs) within the past 2 years (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism; patients with autoimmune-related hypothyroidism receiving stable doses of thyroxine replacement therapy and patients with controllable type 1 diabetes receiving stable doses of insulin are allowed; patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood are allowed; patients with asthma requiring medical intervention with bronchodilators are not allowed). Replacement therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered systemic treatment;\n14. Active hepatitis B patients (including chronic or acute, defined as HBsAg positive at baseline). Previously active HBV infection or cured hepatitis B patients are allowed to enroll if they meet the following conditions: viral hepatitis patients with HBcAb positive and HBsAg negative, with HBV DNA copy number less than the upper limit of normal value of the testing laboratory at the research center before enrollment;\n15. Active hepatitis C patients. HCV antibody-positive patients are allowed to enroll only if HCV RNA test results are negative;\n16. Other liver diseases with known clinically significance, including alcoholic hepatitis or other hepatitis, cirrhosis, hereditary liver diseases;\n17. Known history of HIV positivity or acquired immune deficiency syndrome (AIDS);\n18. Prior receipt of allogeneic stem cell or solid organ transplantation;\n19. Patients with active tuberculosis (TB) who are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year before screening;\n20. Received systemic immunosuppressive drug treatment within 4 weeks before the first administration of the study drug (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[TNF\\]-α drugs). Patients receiving short-term, low-dose systemic immunosuppressive drug treatment or a single bolus of systemic immunosuppressive drugs (e.g., glucocorticoids for 48 hours to treat contrast allergy) may be enrolled in the study after approval by the medical monitor. Patients receiving mineralocorticoids (such as fludrocortisone), corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study;\n21. Any other severe medical condition or abnormal clinical laboratory results that may hinder the patient's safe participation and completion of the study，based on the investigator's judgment","FEMALE","70 Years",{"count":491,"type":21},20,[132],"The goal of this clinical trial is to learn if Tislelizumab Combined with Nab-Paclitaxel works to treat patients of TNBC with bone metastasis as first line treatment. It will also learn about the safety of the combination. The main questions it aims to answer are:\n\nHow effective is the combination therapy of tislelizumab and nab-paclitaxel in treating advanced first-line triple-negative breast cancer with bone metastasis? And is it safe?\n\nParticipants will:\n\n* Receive the treatment as follows: Tislelizumab, 200mg, intravenous, every 3 weeks; nab-paclitaxel, 125mg\u002Fm2 on day 1 and day 8, followed by once every three weeks; RANKL inhibitor chosen by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.\n* Visit the clinic once every 3 weeks for checkups and tests\n* Keep a diary of their symptoms and the number of times they use a rescue inhaler",[495,25],"Triple-negative Breast Cancer","2024-11-22",{"date":498,"type":33},"2024-11-26",{"date":500,"type":33},"2024-08-20",{"date":502,"type":21},"2027-05",{"name":504,"class":40},"Zhejiang Cancer Hospital",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":488,"minAge":512,"maxAge":489,"enrollmentInfo":513,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":41},"100557942","a-study-for-dynamic-prediction-model-of-breast-cancer-bone-metastases-100557942","NCT06544668","A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases","A Clinical Study to Establish a Dynamic Prediction Model for Bone Metastases Based on Breast Cancer Real-world Data","Inclusion Criteria:\n\n1. Patients diagnosed with breast cancer by histopathology;\n2. Age between 20 and 70 years old;\n3. The first diagnosis time is between 2010 and 2020;\n4. Complete diagnosis and treatment information, including basic information, breast cancer diagnosis, surgery, recurrence diagnosis data (including the diagnosis of the metastasis sites), anti-tumor treatment data, bone health and bone metastasis-related diagnosis and treatment data, etc.;\n5. Sufficient available follow-up information.\n\nExclusion Criteria:\n\n1. Missing important basic information (including initial and recurrent pathology, stage, pathological grade and time, surgery time, and drug treatment);\n2. With distant metastasis at the initial diagnosis;\n3. Patients with autoimmune diseases or aggressive viral infections (such as HIV or hepatitis);\n4. Other malignant tumors;\n5. Unclear information about distant metastasis.","20 Years",{"count":514,"type":21},3500,"The purpose of this study is to identify the risk factors of bone metastasis in breast cancer patients so as to develop a dynamic prediction model using real world clinical data. The multicenter data will be retrospectively collected, and the clinical characteristics related to bone metastasis will be analyzed.",[517,25],"Breast Cancer","2024-08-05",{"date":520,"type":33},"2024-08-09",{"date":522,"type":21},"2024-08-06",{"date":524,"type":21},"2025-01-20",{"name":526,"class":40},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":98,"phases":535,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":548},"100553510","safety-of-arcblate-mrghifu-in-patients-with-painful-bone-metastases-an-extension-study-100553510","NCT06487026","Safety of ArcBlate MRgHIFU in Patients With Painful Bone Metastases: An Extension Study","An Extension Study to Evaluate the Safety of ArcBlate MRgHIFU in Patients With Painful Bone Metastases","Inclusion Criteria:\n\n1. Male or female, who randomized into Sham control group and withdrew from CTP-BM-22-01 Study (i.e. main study) due to lack of efficacy.\n2. Completed 14-day evaluation in main study.\n3. Will provide completed and signed written informed consents.\n\nExclusion Criteria:\n\n1. Pregnant women.\n2. Subjects who do not meet any of the inclusion criteria in CTP-BM-22-01 Study (i.e. main study) after re-evaluation.\n3. Determined by the investigator to be not suitable for the conduct of the study for any other reasons.",{"count":7,"type":21},[211],"An Extension Study to Evaluate the Safety of ArcBlate MRgHIFU in Patients with Painful Bone Metastases",[25],"2024-06-27",{"date":540,"type":33},"2024-07-05",{"date":542,"type":21},"2024-08-01",{"date":544,"type":21},"2025-10-31",{"name":546,"class":547},"EpiSonica","INDUSTRY",4,{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":98,"phases":557,"briefSummary":554,"conditions":558,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":548},"100553509","effectiveness-and-safety-of-arcblate-palliative-treatment-for-patients-with-painful-bone-metastases-a-pivotal-study-100553509","NCT06487013","Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study","A Pivotal Study to Evaluate the Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases","Inclusion Criteria:\n\n* Provisional Screening (Screening 1):\n\n  1. Men and women aged 18 and older.\n  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at enrollment.\n  3. Patients who are able and willing to give consent and able to attend all study visits.\n  4. Patients who are suffering from painful bone metastases.\n  5. Patients who refuse other accepted available treatments such as surgery or radiotherapy for pain palliation.\n  6. Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication.\n  7. Able to communicate sensations during the ArcBlate MRgHIFU treatment.\n  8. Patients on ongoing systemic anticancer treatment for at least 2 weeks before treatment:\n* with same systemic anticancer treatment (as documented from patient medical dossier), And\n* worst pain NRS still ≥ 4, And\n* do NOT plan to initiate a new chemotherapy for pain palliation throughout the study duration.\n\n  (9) No radiation therapy to targeted (most painful) lesion in the past two weeks before treatment.\n\n  (10) Bisphosphonate intake should remain stable throughout the study duration. (11) Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated.\n\n  (12) Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated).\n* MRI Screening (Screening 2):\n\n  1. Targeted tumor(s) are ArcBlate MRgHIFU accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5).\n  2. Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.\n  3. Targeted (treated) tumor clearly visible by non-contrast MRI, and ArcBlate MRgHIFU accessible.\n* Sonication Screening (Screening 3):\n\n  1. Subjects could tolerate planned test sonications per randomized treatment.\n\nExclusion Criteria:\n\n* Provisional Screening (Screening 1):\n\n  (1) Patients who either\n* need surgical stabilization of the affected bony structure (\\>7 fracture risk score), Or\n* targeted tumor is at an impending fracture site (\\>7 on fracture risk score), Or\n* patients with surgical stabilization of tumor site with metallic hardware. (2) Targeted (treated) lesion is in the skull. (3) Patients on dialysis. (4) Patients with life expectancy \\\u003C 3-Months. (5) Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.\n\n  (6) Patients with unstable cardiac status including:\n* Unstable angina pectoris on medication,\n* Patients with documented myocardial infarction within six months of protocol entry,\n* Congestive heart failure requiring medication (other than diuretic),\n* Patients on anti-arrhythmic drugs. (7) Severe hypertension (diastolic blood pressure \\> 100 mmHg on medication). (8) Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations (unable to fit into ArcBlate MRgHIFU), etc.\n\n  (9) Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.\n\n  (10) Known intolerance or allergies to the MRI contrast agent (e.g., Gadolinium or Magnevist) and Computed Tomography (CT) contrast agent including advanced kidney disease.\n\n  (11) Severe cerebrovascular disease (multiple CerebroVascular Accident (CVA) or CVA within 6 months).\n\n  (12) Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.).\n\n  (13) Are participating or have participated in another clinical trial in the last 30 days.\n\n  (14) Patients initiating a new chemotherapy regime, or radiation (for the targeted most painful lesion) within the last 2 weeks before treatment.\n\n  (15) Patients unable to communicate with the investigator and staff. (16) Patients with persistent undistinguishable pain (pain source unidentifiable).\n\n  (17) The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.\n\n  (18) Patients with calcified treatment area. (19) Pregnant women.\n* MRI Screening (Screening 2):\n\n  1. Target (treated) lesion is less than 10-mm from nerve bundles, bowels or bladder.\n  2. Extensive scarring in the energy path of the planned treatment area",{"count":209,"type":21},[211],[25],{"date":540,"type":33},{"date":561,"type":33},"2023-12-08",{"date":563,"type":21},"2025-09-30",{"name":546,"class":547},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":573,"targetDuration":512,"studyType":22,"phases":4,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":586},"100544331","national-database-of-bone-metastases-100544331","NCT06367491","National Database of Bone Metastases","Banca Dati Nazionale Metastasi Ossee","BDMO","Inclusion Criteria:\n\n* Radiological and\u002For histological diagnosis of bone metastasis from histologically established solid tumor\n* Males or females aged \\>= 18 years\n* Informed consent\n\nExclusion Criteria:\n\n* Not applicable",{"count":574,"type":21},800,"BDMO is an Italian multicentre, observational, prospective study that collects data from all patients with bone metastases referred to each participating centre, using an on-line software 'tailor-made' for data collection.",[25],"2024-04-11",{"date":579,"type":33},"2024-04-16",{"date":581,"type":33},"2013-10-08",{"date":583,"type":21},"2030-01-01",{"name":585,"class":40},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS",30,{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":512,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":98,"phases":595,"briefSummary":596,"conditions":597,"keywords":601,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":4},"100513745","short-versus-long-intramedullary-nails-in-the-treatment-of-proximal-femur-metastasis-100513745","NCT05969470","Short Versus Long Intramedullary Nails in the Treatment of Proximal Femur Metastasis.","Compare the Efficacy of Long-nailed and Short-nailed Fixation for Proximal Femur Metastasis - a Non-inferior Randomized Controlled Trial","Inclusion Criteria:\n\n* Femur (impending) pathological fracture that is suitable for intramedullary nail fixation as determined by the physician\n* Patient is willing to participate in this clinical trial and cooperate with follow-up\n\nExclusion Criteria:\n\n* The patient has a more appropriate treatment alternative to single intramedullary nail fixation as determined by the multidisciplinary decision, such as,\n\n  * The metastatic lesions involved the femur head\n  * The metastatic lesions involved the pelvis\n  * The metastatic lesions compromised the greater or lesser trochanter to a certain extent that arthroplasty was indicated\n  * The metastatic lesions involved\u002Foccurred more distal than the intertrochanteric line\n* There are justified, clinically significant rationales that either long or short intramedullary nails be a more appropriate treatment during pre-operative assessment\n* The patient has imaging-confirmed distant femoral metastases before treatment\n* Patient has renal cell carcinoma or sarcoma\n* Patient is unable to cooperate with follow-up or to understand the trial protocol\n* Patient is unable to communicate in Chinese",{"count":158,"type":21},[211],"The goal of this interventional randomized controlled trial is to compare the clinical outcomes in treating extremities pathological fractures (fractures of limbs caused by metastatic tumors) or impending pathological fractures with short or long intramedullary nails. The main questions it aims to answer are:\n\n1. What is the rate of developing new distant metastasis of the operated extremities?\n2. Does treating extremities (impending) pathological fractures with long intramedullary nails have lower or similar reoperation rate than the short nails?\n3. Are there any differences when comparing the surgical-related complication, functional outcomes and life quality assessment between treating extremities (impending) pathological fractures with long or short intramedullary nails.\n\nParticipants who meet surgical indication will be randomized into either the long or short intramedullary nail group after informed consent. The patient will receive bone fixation with the corresponding prosthesis.",[25,598,599,600],"Pathological Fracture","Pathological Fracture, Left Femur","Pathological Fracture, Right Femur",[602,603,25,604],"Long Intramedullary Nails","Short Intramedullary Nails","Pathological Fracture of Femur","2023-08-15",{"date":607,"type":33},"2023-08-18",{"date":609,"type":21},"2023-08-31",{"date":611,"type":21},"2027-06",{"name":613,"class":40},"National Taiwan University Hospital"]